This marks the second product that ANI is launching from the basket of 22 previously marketed generic products that it acquired in July 2015.
“This launch represents yet another successful manufacturing site transfer and re-commercialization of a previously discontinued ANDA product,” said Arthur Przybyl, president and chief executive officer, ANI. “We will continue to leverage our U.S.-based manufacturing assets as we aim to launch additional products manufactured at these sites in 2017."
Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention (swelling) associated with congestive heart failure.